Sowmya Viswanathan, Ph.D. - Publications

2003 University of Toronto, Toronto, ON, Canada 
Biomedical Engineering, Cell Biology

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Rashedi I, Gomez-Aristizábal A, Wang XH, Viswanathan S, Keating A. TLR3 or TLR4 Activation Enhances MSC-Mediated Treg Induction via Notch Signaling. Stem Cells (Dayton, Ohio). PMID 27571579 DOI: 10.1002/stem.2485  0.88
2016 Gómez-Aristizábal A, Kim KP, Viswanathan S. A Systematic Study of the Effect of Different Molecular Weights of Hyaluronic Acid on Mesenchymal Stromal Cell-Mediated Immunomodulation. Plos One. 11: e0147868. PMID 26820314 DOI: 10.1371/journal.pone.0147868  0.88
2015 Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, ... ... Viswanathan S, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. PMID 26724220 DOI: 10.1016/j.jcyt.2015.11.008  0.88
2015 Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw S, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M, Soares M, Viswanathan S. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative Medicine. 10: 897-911. PMID 26565607 DOI: 10.2217/rme.15.51  0.88
2015 Viswanathan S, Bubela T. Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Regenerative Medicine. 10: 647-63. PMID 26237706 DOI: 10.2217/rme.15.28  0.88
2015 Montanari S, Dayan V, Yannarelli G, Billia F, Viswanathan S, Connelly KA, Keating A. Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 26234284 DOI: 10.1016/j.healun.2015.05.008  0.88
2015 Wolfstadt JI, Cole BJ, Ogilvie-Harris DJ, Viswanathan S, Chahal J. Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis. Sports Health. 7: 38-44. PMID 25553211 DOI: 10.1177/1941738114529727  0.88
2014 Feigal EG, Tsokas K, Viswanathan S, Zhang J, Priest C, Pearce J, Mount N. Proceedings: international regulatory considerations on development pathways for cell therapies. Stem Cells Translational Medicine. 3: 879-87. PMID 25038248 DOI: 10.5966/sctm.2014-0122  0.88
2014 Montanari S, Wang XH, Yannarelli G, Dayan V, Berger T, Zocche L, Kobayashi E, Viswanathan S, Keating A. Development and characterization of a new inbred transgenic rat strain expressing DsRed monomeric fluorescent protein. Transgenic Research. 23: 779-93. PMID 25011565 DOI: 10.1007/s11248-014-9814-z  0.88
2014 Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, Mason C, Rao MS. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells and Development. 23: 1157-67. PMID 24422625 DOI: 10.1089/scd.2013.0591  0.88
2014 Lazarova T, Mlynarczyk K, Filipek S, Kolinski M, Wassenaar TA, Querol E, Renugopalakrishnan V, Viswanathan S, Padrós E. The effect of triple glutamic mutations E9Q/E194Q/E204Q on the structural stability of bacteriorhodopsin. The Febs Journal. 281: 1181-95. PMID 24341610 DOI: 10.1111/febs.12694  0.88
2014 Yannarelli G, Tsoporis JN, Desjardins JF, Wang XH, Pourdjabbar A, Viswanathan S, Parker TG, Keating A. Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction. Stem Cell Reviews. 10: 304-15. PMID 24287730 DOI: 10.1007/s12015-013-9483-y  0.88
2013 Dudzik J, Chang WC, Kannan AM, Filipek S, Viswanathan S, Li P, Renugopalakrishnan V, Audette GF. Cross-linked glucose oxidase clusters for biofuel cell anode catalysts. Biofabrication. 5: 035009. PMID 23880606 DOI: 10.1088/1758-5082/5/3/035009  0.88
2013 Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Translational Medicine. 2: 607-13. PMID 23836804 DOI: 10.5966/sctm.2013-0019  0.88
2013 Pulawski W, Filipek S, Zwolinska A, Debinski A, Krzysko K, Garduño-Juárez R, Viswanathan S, Renugopalakrishnan V. Low-temperature molecular dynamics simulations of horse heart cytochrome c and comparison with inelastic neutron scattering data. European Biophysics Journal : Ebj. 42: 291-300. PMID 23224355 DOI: 10.1007/s00249-012-0874-9  0.88
2013 Viswanathan S, Joshi C. Regenerative medicine: challenges and perspectives for successful therapies. Current Topics in Microbiology and Immunology. 367: 101-12. PMID 23208552 DOI: 10.1007/82_2012_290  0.88
2012 Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells and Development. 21: 2724-52. PMID 22468918 DOI: 10.1089/scd.2011.0722  0.88
2012 Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, Martinez-Lopez J, Keating A. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 97: 1020-8. PMID 22271890 DOI: 10.3324/haematol.2011.054254  0.88
2011 Viswanathan S, Keating A. Overcoming the challenges of conducting translational research in cell therapy. Frontiers of Medicine. 5: 333-5. PMID 22198744 DOI: 10.1007/s11684-011-0166-2  0.88
2011 Viswanathan S, Kosaka Y. Review of recent Clinical developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells Recent Patents On Regenerative Medicine. 1: 228-248.  0.88
2005 Viswanathan S, Davey RE, Cheng D, Raghu RC, Lauffenburger DA, Zandstra PW. Clonal evolution of stem and differentiated cells can be predicted by integrating cell-intrinsic and -extrinsic parameters. Biotechnology and Applied Biochemistry. 42: 119-31. PMID 15882145 DOI: 10.1042/BA20040207  0.88
2003 Viswanathan S, Zandstra PW. Towards predictive models of stem cell fate. Cytotechnology. 41: 75-92. PMID 19002945 DOI: 10.1023/A:1024866504538  0.88
2003 Viswanathan S, Benatar T, Mileikovsky M, Lauffenburger DA, Nagy A, Zandstra PW. Supplementation-dependent differences in the rates of embryonic stem cell self-renewal, differentiation, and apoptosis. Biotechnology and Bioengineering. 84: 505-17. PMID 14574685 DOI: 10.1002/bit.10799  0.88
2002 Viswanathan S, Benatar T, Rose-John S, Lauffenburger DA, Zandstra PW. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells (Dayton, Ohio). 20: 119-38. PMID 11897869 DOI: 10.1634/stemcells.20-2-119  0.88
Show low-probability matches.